{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:21:33Z","timestamp":1789676493063,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31991174"],"award-info":[{"award-number":["31991174"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Basic Research Center of China","award":["82388101"],"award-info":[{"award-number":["82388101"]}]},{"DOI":"10.13039\/501100002855","name":"Ministry of Science and Technology of the People's Republic of China","doi-asserted-by":"publisher","award":["2022YFC2505001"],"award-info":[{"award-number":["2022YFC2505001"]}],"id":[{"id":"10.13039\/501100002855","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dendritic cells (DCs) play a predominant role in antitumor immunity. As professional antigen-presenting cells (APCs), DCs can be functionally matured by TLR2 ligand binding to enhance innate immune response and subsequent T cell-dependent adaptive immunity. DC function is often suppressed by the tumor microenvironment, while current TLR2 agonists exhibit suboptimal stability and diminished efficacy in vivo. Therefore, reactivation of suppressed DCs could be a promising strategy for enhancing the efficacy of cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>To investigate the antitumor immunity induced by the novel Toll-like receptor 2 (TLR2) agonist SUP3 with better stability, we established murine melanoma, colon cancer and breast cancer tumor models. The hematopoietic growth factor Flt3L-dependent dendritic cells (FLDCs) were generated and utilized to examine their capacities of antigen processing and cross-presentation, and migration to the tumor-draining lymph nodes (TdLNs) in response to SUP3 treatment. To further improve the antitumor response of SUP3 by increasing the abundance and activation of DCs, Flt3L was administrated in vivo in combination with immune checkpoint blockade.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>SUP3 exhibited stronger inhibition of tumor growth and metastasis than classical TLR2 agonist, Pam3. SUP3 could increase cDC1 antigen cross-presentation and TdLN migration, promoting the proliferation, activation and cytotoxicity of antigen-specific cytotoxic T lymphocytes (CTL). SUP3 promoted the intracellular accumulation of antigens and facilitated the process of antigen cross-presentation, the processe regulated by the small GTPase Rab7. SUP3 induced PD-L1 expression by DCs via an interferon-\u03b3-independent pathway. The combination of SUP3 treatment with immune checkpoint blockade by anti-PD-L1 further improved the antitumor response. Moreover, Flt3L increased DC proliferation and infiltration into the tumor tissues that further enhanced the effects of antitumor immunotherapy when used in combination with SUP3 and anti-PD-L1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study demonstrated that the modified and more stable TLR2 agonist SUP3 provided an optimal strategy for promoting antitumor immunity via activation of cDC1. SUP3 enhanced antigen cross-presentation by cDC1 and subsequent activation of CTLs. The antitumor effect was further enhanced when SUP3 and Flt3L synergized with PD-L1 blockade. Therefore, reactivation of suppressed DCs in tumor microenvironment would be a promising strategy for designing effective antitumor immunotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13046-025-03571-9","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:29:39Z","timestamp":1764073779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Enhancing anti-tumour immunity through modulating dendritic cell activation by combination therapy with a novel TLR2 agonist and PD-L1 Blockade"],"prefix":"10.1186","volume":"44","author":[{"given":"Chao","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenkang","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanhao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maocai","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaoyan","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueheng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhisong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuebin","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"issue":"5","key":"3571_CR1","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1084\/jem.137.5.1142","volume":"137","author":"RM Steinman","year":"1973","unstructured":"Steinman RM, Cohn ZA. Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution. J Exp Med. 1973;137(5):1142\u201362.","journal-title":"J Exp Med"},{"issue":"6","key":"3571_CR2","first-page":"942","volume":"52","author":"SL Nutt","year":"2020","unstructured":"Nutt SL, Chopin M. Transcriptional Networks Driv Dendritic Cell Differ Function Immun. 2020;52(6):942\u201356.","journal-title":"Transcriptional Networks Driv Dendritic Cell Differ Function Immun"},{"issue":"7559","key":"3571_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature14404","volume":"523","author":"S Spranger","year":"2015","unstructured":"Spranger S, Bao R, Gajewski TF. Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity. Nature. 2015;523(7559):231\u20135.","journal-title":"Nature"},{"issue":"5904","key":"3571_CR4","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1164206","volume":"322","author":"K Hildner","year":"2008","unstructured":"Hildner K, et al. Batf3 deficiency reveals a critical role for CD8alpha\u2009+\u2009dendritic cells in cytotoxic T cell immunity. Science. 2008;322(5904):1097\u2013100.","journal-title":"Science"},{"issue":"2","key":"3571_CR5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ccell.2016.06.003","volume":"30","author":"EW Roberts","year":"2016","unstructured":"Roberts EW, et al. Critical role for CD103(+)\/CD141(+) dendritic cells bearing CCR7 for tumor antigen trafficking and priming of T cell immunity in melanoma. Cancer Cell. 2016;30(2):324\u201336.","journal-title":"Cancer Cell"},{"issue":"4","key":"3571_CR6","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.immuni.2016.03.012","volume":"44","author":"H Salmon","year":"2016","unstructured":"Salmon H, et al. Expansion and activation of CD103(+) dendritic cell progenitors at the tumor site enhances tumor responses to therapeutic PD-L1 and BRAF Inhibition. Immunity. 2016;44(4):924\u201338.","journal-title":"Immunity"},{"key":"3571_CR7","doi-asserted-by":"crossref","unstructured":"Gerhard GM et al. Tumor-infiltrating dendritic cell States are conserved across solid human cancers. J Exp Med. 2021 Jan 4;218(1):e20200264.","DOI":"10.1084\/jem.20200264"},{"issue":"1","key":"3571_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","volume":"131","author":"B Rowshanravan","year":"2018","unstructured":"Rowshanravan B, Halliday N, Sansom DM. CTLA-4: a moving target in immunotherapy. Blood. 2018;131(1):58\u201367.","journal-title":"Blood"},{"issue":"5","key":"3571_CR9","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1016\/j.ccell.2014.09.007","volume":"26","author":"ML Broz","year":"2014","unstructured":"Broz ML, et al. Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. Cancer Cell. 2014;26(5):638\u201352.","journal-title":"Cancer Cell"},{"key":"3571_CR10","doi-asserted-by":"crossref","unstructured":"Zhang S, Chopin M, Nutt SL. Type 1 conventional dendritic cells: ontogeny, function, and emerging roles in cancer immunotherapy. Trends in Immunology; 2021Dec;42(12):1113\u20131127.","DOI":"10.1016\/j.it.2021.10.004"},{"issue":"2","key":"3571_CR11","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, et al. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173(2):945\u201354.","journal-title":"J Immunol"},{"issue":"1","key":"3571_CR12","doi-asserted-by":"publisher","first-page":"4835","DOI":"10.1038\/s41467-020-18570-x","volume":"11","author":"Q Peng","year":"2020","unstructured":"Peng Q, et al. PD-L1 on dendritic cells attenuates T cell activation and regulates response to immune checkpoint Blockade. Nat Commun. 2020;11(1):4835.","journal-title":"Nat Commun"},{"key":"3571_CR13","doi-asserted-by":"crossref","unstructured":"Bhardwaj N et al. Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. Nat Cancer, 2020 Dec;1(12):1204\u20131217.","DOI":"10.1038\/s43018-020-00143-y"},{"issue":"2","key":"3571_CR14","first-page":"443","volume":"200","author":"PM Santos","year":"2018","unstructured":"Santos PM, Butterfield LH. Dendritic Cell-Based Cancer Vaccines J Immunol. 2018;200(2):443\u20139.","journal-title":"Dendritic Cell-Based Cancer Vaccines J Immunol"},{"key":"3571_CR15","doi-asserted-by":"crossref","unstructured":"Guo X et al. The novel Toll-Like receptor 2 agonist SUP3 enhances antigen presentation and T cell activation by dendritic cells. Front Immunol. 2017 Feb 21;8:158.","DOI":"10.3389\/fimmu.2017.00158"},{"issue":"5","key":"3571_CR16","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2017.04.003","volume":"31","author":"S Spranger","year":"2017","unstructured":"Spranger S, et al. Tumor-Residing Batf3 dendritic cells are required for effector T cell trafficking and adoptive T cell therapy. Cancer Cell. 2017;31(5):711\u201323. e4.","journal-title":"Cancer Cell"},{"issue":"1","key":"3571_CR17","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2006.05.035","volume":"126","author":"A Savina","year":"2006","unstructured":"Savina A, et al. NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell. 2006;126(1):205\u201318.","journal-title":"Cell"},{"issue":"10","key":"3571_CR18","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/tra.12587","volume":"19","author":"B Cabukusta","year":"2018","unstructured":"Cabukusta B, Neefjes J. Mechanisms of lysosomal positioning and movement. Traffic. 2018;19(10):761\u20139.","journal-title":"Traffic"},{"issue":"6","key":"3571_CR19","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1016\/j.immuni.2015.11.006","volume":"43","author":"A Alloatti","year":"2015","unstructured":"Alloatti A, et al. Toll-like receptor 4 engagement on dendritic cells restrains Phago-Lysosome fusion and promotes Cross-Presentation of antigens. Immunity. 2015;43(6):1087\u2013100.","journal-title":"Immunity"},{"issue":"8","key":"3571_CR20","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/nri3254","volume":"12","author":"OP Joffre","year":"2012","unstructured":"Joffre OP, et al. Cross-presentation by dendritic cells. Nat Rev Immunol. 2012;12(8):557\u201369.","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"3571_CR21","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrm2728","volume":"10","author":"H Stenmark","year":"2009","unstructured":"Stenmark H. Rab GTPases as coordinators of vesicle traffic. Nat Rev Mol Cell Biol. 2009;10(8):513\u201325.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"3","key":"3571_CR22","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1042\/BSR20090032","volume":"29","author":"M Zhang","year":"2009","unstructured":"Zhang M, et al. Rab7: roles in membrane trafficking and disease. Biosci Rep. 2009;29(3):193\u2013209.","journal-title":"Biosci Rep"},{"key":"3571_CR23","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fimmu.2012.00037","volume":"3","author":"EB Compeer","year":"2012","unstructured":"Compeer EB, et al. Antigen processing and remodeling of the endosomal pathway: requirements for antigen cross-presentation. Front Immunol. 2012;3:37.","journal-title":"Front Immunol"},{"issue":"2","key":"3571_CR24","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1158\/2326-6066.CIR-16-0391","volume":"5","author":"T Noguchi","year":"2017","unstructured":"Noguchi T, et al. Temporally distinct PD-L1 expression by tumor and host cells contributes to immune escape. Cancer Immunol Res. 2017;5(2):106\u201317.","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"3571_CR25","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1002\/eji.200939289","volume":"40","author":"S Karakhanova","year":"2010","unstructured":"Karakhanova S, et al. ERK\/p38 MAP-kinases and PI3K are involved in the differential regulation of B7-H1 expression in DC subsets. Eur J Immunol. 2010;40(1):254\u201366.","journal-title":"Eur J Immunol"},{"issue":"6","key":"3571_CR26","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s10147-017-1161-7","volume":"22","author":"X Zhang","year":"2017","unstructured":"Zhang X, et al. PD-L1 induced by IFN-gamma from tumor-associated macrophages via the JAK\/STAT3 and PI3K\/AKT signaling pathways promoted progression of lung cancer. Int J Clin Oncol. 2017;22(6):1026\u201333.","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"3571_CR27","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1182\/blood-2009-12-255125","volume":"116","author":"A Kondo","year":"2010","unstructured":"Kondo A, et al. Interferon-gamma and tumor necrosis factor-alpha induce an Immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood. 2010;116(7):1124\u201331.","journal-title":"Blood"},{"issue":"7","key":"3571_CR28","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1038\/s43018-020-0075-x","volume":"1","author":"SA Oh","year":"2020","unstructured":"Oh SA, et al. PD-L1 expression by dendritic cells is a key regulator of T-cell immunity in cancer. Nat Cancer. 2020;1(7):681\u201391.","journal-title":"Nat Cancer"},{"key":"3571_CR29","doi-asserted-by":"crossref","unstructured":"Mayoux M et al. Dendritic cells dictate responses to PD-L1 Blockade cancer immunotherapy. Sci Transl Med. 2020 Mar 11;12(534):eaav7431.","DOI":"10.1126\/scitranslmed.aav7431"},{"issue":"8","key":"3571_CR30","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-018-0085-8","volume":"24","author":"KC Barry","year":"2018","unstructured":"Barry KC, et al. A natural killer-dendritic cell axis defines checkpoint therapy-responsive tumor microenvironments. Nat Med. 2018;24(8):1178\u201391.","journal-title":"Nat Med"},{"issue":"27","key":"3571_CR31","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1038\/onc.2013.302","volume":"33","author":"JP Pradere","year":"2014","unstructured":"Pradere JP, Dapito DH, Schwabe RF. The Yin and Yang of Toll-like receptors in cancer. Oncogene. 2014;33(27):3485\u201395.","journal-title":"Oncogene"},{"issue":"7318","key":"3571_CR32","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1038\/nature09421","volume":"467","author":"XZ West","year":"2010","unstructured":"West XZ, et al. Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands. Nature. 2010;467(7318):972\u20136.","journal-title":"Nature"},{"issue":"4","key":"3571_CR33","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ccr.2012.08.010","volume":"22","author":"H Tye","year":"2012","unstructured":"Tye H, et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell. 2012;22(4):466\u201378.","journal-title":"Cancer Cell"},{"issue":"12","key":"3571_CR34","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1016\/j.celrep.2015.11.053","volume":"13","author":"M Tang","year":"2015","unstructured":"Tang M, et al. Toll-like receptor 2 activation promotes tumor dendritic cell dysfunction by regulating IL-6 and IL-10 receptor signaling. Cell Rep. 2015;13(12):2851\u201364.","journal-title":"Cell Rep"},{"issue":"7225","key":"3571_CR35","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature07623","volume":"457","author":"S Kim","year":"2009","unstructured":"Kim S, et al. Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature. 2009;457(7225):102\u20136.","journal-title":"Nature"},{"key":"3571_CR36","doi-asserted-by":"crossref","unstructured":"Wu CC et al. A Toll-like receptor 2 agonist-fused antigen enhanced antitumor immunity by increasing antigen presentation and the CD8 memory T cells population. Oncotarget. (Electronic). 2016;1949\u20132553.","DOI":"10.18632\/oncotarget.9001"},{"issue":"37","key":"3571_CR37","doi-asserted-by":"publisher","first-page":"E8698","DOI":"10.1073\/pnas.1809232115","volume":"115","author":"Y Wang","year":"2018","unstructured":"Wang Y, et al. Adjuvant effect of the novel TLR1\/TLR2 agonist Diprovocim synergizes with anti-PD-L1 to eliminate melanoma in mice. Proc Natl Acad Sci U S A. 2018;115(37):E8698\u2013706.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"3571_CR38","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1002\/eji.201444722","volume":"45","author":"AM McDonnell","year":"2015","unstructured":"McDonnell AM, et al. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol. 2015;45(1):49\u201359.","journal-title":"Eur J Immunol"},{"issue":"1","key":"3571_CR39","doi-asserted-by":"publisher","first-page":"61","DOI":"10.4049\/jimmunol.176.1.61","volume":"176","author":"O Preynat-Seauve","year":"2005","unstructured":"Preynat-Seauve O, et al. Tumor-Infiltrating dendritic cells are potent Antigen-Presenting cells able to activate T cells and mediate tumor rejection. J Immunol. 2005;176(1):61\u20137.","journal-title":"J Immunol"},{"issue":"1","key":"3571_CR40","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","volume":"20","author":"SK Wculek","year":"2020","unstructured":"Wculek SK, et al. Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2020;20(1):7\u201324.","journal-title":"Nat Rev Immunol"},{"issue":"10","key":"3571_CR41","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1158\/2159-8290.CD-18-0280","volume":"8","author":"A Ribas","year":"2018","unstructured":"Ribas A, et al. SD-101 in combination with pembrolizumab in advanced melanoma: results of a phase Ib, multicenter study. Cancer Discov. 2018;8(10):1250\u20137.","journal-title":"Cancer Discov"},{"issue":"6","key":"3571_CR42","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/nm0697-625","volume":"3","author":"DH Lynch","year":"1997","unstructured":"Lynch DH, et al. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med. 1997;3(6):625\u201331.","journal-title":"Nat Med"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03571-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03571-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03571-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T12:29:41Z","timestamp":1764073781000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03571-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3571"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03571-9","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"9 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Animals were bred and maintained at Tsinghua University in a specific pathogen-free facility at the Laboratory Animal Resources Center. All procedures involving mouse manipulation and all experimental protocols in this study were approved by the Institutional Animal Care and Use Committees of Tsinghua University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"311"}}